COCHEnvoy Medical Inc. Class A Common Stock
Envoy Medical, Inc., a hearing health company, provides medical technologies across the hearing loss spectrum. The company's medical technologies are designed to shift the paradigm within the hearing industry and bring p…
Industry Peers
Medical Devices| Headline | Source | Time |
|---|---|---|
Older | ||
 Are Medical Stocks Lagging Compugen (CGEN) This Year? Here is how Compugen (CGEN) and Envoy Medical, Inc. (COCH) have performed compared to their sector so far this year. | ||
 Envoy Medical, Inc. (COCH) Reports Q2 Loss, Misses Revenue Estimates Envoy Medical, Inc. (COCH) delivered earnings and revenue surprises of +22.22% and -15.00%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Envoy Medical, Inc. (COCH) May Report Negative Earnings: Know the Trend Ahead of Q2 Release Envoy Medical, Inc. (COCH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. | ||
 EXCLUSIVE: Envoy Medical Hits Key Clinical Trial Milestone for Fully Implanted Ear Implant Envoy Medical Inc. (NASDAQ:COCH) on Tuesday said it surpassed the three-month milestone for all 56 patients enrolled in the company’s pivotal clinical trial evaluating the investigational fully implanted Acclaim cochlear implant. Envoy Medical Completes Three-Month Milestone In Acclaim Trial The update marks another important clinical trial milestone as the company continues to build momentum with the hearing industry. Read Also: EXCLUSIVE: Envoy Medical Hits Trial Milestone For Cochlear Implant | ||
 EXCLUSIVE: Envoy Medical Builds Momentum With Improved Cochlear Implant Trial Results Envoy Medical Inc. (NASDAQ:COCH) on Tuesday reported 12-month results from the first 10 participants in Stage 1 of its pivotal clinical trial evaluating the investigational fully implanted Acclaim cochlear implant, with hearing performance continuing to improve over previously reported six-month data. The company said participants achieved a mean Consonant-Nucleus-Consonant (CNC) word recognition score of 53.2% at the 12-month mark, compared with a pre-implantation baseline of 15.2%. The 38.0 pe | ||
 AngioDynamics (ANGO) Reports Q4 Loss, Beats Revenue Estimates AngioDynamics (ANGO) delivered earnings and revenue surprises of +36.36% and +7.61%, respectively, for the quarter ended May 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 TransMedics (TMDX) Q1 Earnings and Revenues Miss Estimates TransMedics (TMDX) delivered earnings and revenue surprises of -51.46% and -0.99%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Positive Signs As Multiple Insiders Buy Envoy Medical Stock Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying... | ||
 Envoy Medical, Inc. (COCH) Upgraded to Buy: Here's Why Envoy Medical, Inc. (COCH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). | ||
 Envoy Medical, Inc. (COCH) Reports Q3 Loss, Misses Revenue Estimates Envoy Medical, Inc. (COCH) delivered earnings and revenue surprises of -29.63% and -23.64%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock? | ||